Using an immunogold staining technique and electron microscopy, w e investigated the localization of the a-granule pool of glycoprotein (GP) Ilb-llla in normal platelets and maturing megakaryocytes (MK), in pathologic platelets from a patient with type I Glanzmann's thrombasthenia (GT), and from three patients with the gray platelet syndrome (GPS). In normal resting platelets, GPllb-llla was observed on the plasmatic side of the plasma membrane, the open canicular system (OCS) membranes, and along the internal face of the a-granule membrane. This location was found with three monospecific polyclonal antibodies: one anti-GPllb-llla antibody, the second specific for GPllb, and the third specific for GPllla. After thrombin stimulation, the a-granule labeling disappeared whereas membrane labeling increased. Platelets from GT did not display labeling on plasma membranes, OCS membranes, or a-granule membranes. Platelets from the three patients with GPS displayed intense labeling of the plasma membrane and the
LYCOPROTEIN (GP) IIb-IIIa is a major component
G of the platelet plasma membrane where it functions after appropriate stimulation as an aggregation receptor for adhesive ~r0teins.l.~ Initial evidence for this receptor function was provided by studies from Glanzmann's thrombasthenia (GT), a congenital bleeding disease characterized by the absence of GPIIb-IIIa from the platelet m e m b r a~~e .~.~ Some evidence has been presented recently indicating that GPIIbIIIa is also present on the membrane of a-granules: subcellular fractionation data' predicted the existence of an internal pool of these GPs rendered accessible by thrombin stimulation, and thus possibly associated with a -g r a n~l e s .~~" This evidence was supported by immunocytochemical observations performed with a polyclonal antibodyI2; however, when a panel of monoclonal antibodies (MoAbs) to the GPIIb-IIIa complex was used (although heavy labeling of the plasma membrane and open canalicular system [OCS] was obtained), no a-granule labeling was observed by these investigators.I2 In contrast to the above observations, the we apply this study to platelets from patients with G T and the gray platelet syndrome (GPS), which is defined by a congenital absence of normal a-gran~1es.l~ Indeed, the recognition and characterization of a granule-associated GPIIbIIIa pool may be of importance in understanding the role of degranulation in platelet function as well as the role of the complex in stabilizing fibrinogen within a-granules.
MATERIALS AND METHODS

Cells
Blood platelet samples were taken from three normal healthy volunteers, from three patients with GPS (HBpital Lariboisibre, Paris, France),16 and from one patient with GT type I (courtesy of Dr D. Meyer, HBpital de Bicetre, Paris, France). Blood samples were harvested by venipuncture into plastic tubes containing either sodium EDTA as an anticoagulant or 9 vol of fixative (either 4% paraformaldehyde or 1% glutaraldehyde in 0.1 mol/L phosphate buffer, pH 7.4) for each volume of blood.
Bone marrow was obtained from two normal marrow graft donors. MK were grown in liquid culture from light density normal bone marrow cells (density < 1.077) isolated on a Ficoll metrizoate gradient. The medium contained 1% bovine serum albumin (Sigma Chemicals, St Louis, MO), 10% aplastic plasma, and 2.5% phytohemagglutinin-leukocyte-conditioned medium.
Cells were grown at high concentration (5.10' to 1.106/mL) in 75 cm2 culture flasks (Corning Glasswork Co, Corning, NY). The cells growing in suspension were transferred each day, from day 6, into a new culture flask to eliminate adherent cells. This procedure allowed a great enrichment in MK. The cells were further treated as previously described16 and embedded in glycol-methacrylate. 
Platelets.
MK.
Antibodies
Preparation of an afinity-purified rabbit anti-GPllb-IlIa antibody. Purified and dissociated GPIIb-Illa was prepared as previously described." A rabbit antibody was raised against purified, dissociated GPIlb-IIla complex by conventional immunization procedures'* and was affinity-purified on dissociated GPIIb-IIla complex coupled to Affigel 10/15 (Bio-Rad. Richmond, CA). Bound antibody was eluted with 0.1 mol/L glycine, pH 2.4; the eluted fractions were immediately neutralized by the addition of one-fifth vol of I mol/L Tris. pH 8.5, and then dialyzed exhaustively against 0.01 mol/L Tris, 0.15 mol/L sodium chloride, pH 7.4. The purified antibody gave a single immunoprecipitin arc on crossed immunoelectrophoresis of Triton X-100 solubilized platelets (BDH Chemicals, Ltd, Pool, England)'8.'9 that corresponded to GPIIb-IIIa complex, and specifically immunoprecipitated GPIIb-IIIa complex from lactoperoxidase radioiodinated and Triton X-1 Wolubilized platelets." Western blot analysis was performed essentially as previously described" using the affinity-purified rabbit anti-GPIIb-IIIa antibody with washed human platelets electrophoresed on a 5% to 15% exponential sodium dodecyl sulfate (SDS)-polyacrylamide gel under nonreducing and reducing conditions.
To raise polyclonal rabbit antibodies against separated and purified GPIIb and GPIlla, the GPIIb-IIIa complex was first isolated from Triton X-100 soluble platelet extracts by affinity chromatography as previously described." Separation of GPlIb from GPllla was obtained after solubilization of the purified GPIlb-IIIa complex in 2% (wt/vol) SDS. 30 pmol/L NEM at IOOOC for 5 minutes followed by preparative SDS-PAGE into 3-mm thick 7% acrylamide gels. Individual GPs were separately recovered from gel sections and concentrated by electroelution using a Biotrap apparatus (Schleicher and Schuell. Dassel. FRG). Purity of each molecular species was assessed by SDS-PAGE analysis followed by either sensitive silver nitrate staining or by electrotransfer to nitrocellulose membranes followed by immunoblotting using murine MoAbs specific for GPllb or GPIIIa. Two New Zealand white rabbits were immunized with each purified GP. A strong positive response was observed in all animals 5 weeks after immunization. The same unfractionated antisera against GPIIb or GPIIla were used throughout this study, whose respective specificities for GPIIb and GPIIIa were assessed through Western blot analysis of total platelet proteins.
Preparation of anti-GPIIb and anti-GPlIIa antibodies.
Immunogold Staining
The immunocytochemical reactions were performed on thin sections as previously described.I6 Goat anti-rabbit immunoglobulin fractions coupled to 5-nm colloidal gold particles (GAR G5) were used as the dense probe and purchased from Janssen Pharmaceutica (Beerse. Belgium). They were used at a 1:lO dilution. The platelets from the patient with GT were used as controls for the specificity of the anti-GPllb-IIIa antibodies. As an additional control, sections were incubated in nonimmune normal rabbit serum instead of primary antisera, followed by GAR GS.
RESULTS
Specificity of Polyclonal Antibodies
The majority of the immunogold localization studies used an affinity-purified rabbit antibody against the dissociated GPIIb-IIIa complex. Figure 1A 
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SDS-PAGE migration positions of GPIIb and GPIIIa (nonreduced), and GPIIb a, GPIIIa, and GPIIb / 3 (reduced) in SDS polyacrylamide gels. Figure 1 B depicts the specificity of the rabbit antisera raised against the purified GPIIb or GPIIIa, as established by a similar Western blot technique. Each antiserum demonstrates a strong reactivity with its own platelet antigen, and does not show any cross-reactivity with the other GP or other platelets' components.
Normal Platelets
On intact resting blood platelets (Fig 2) , labeling of GPIIb-IIIa was observed on the outside face of the plasma membrane and on the intraluminal side of the OCS according to a patchy distribution pattern. Moreover, the internal side of the a-granule membrane displayed intense labeling for GPIIb-IIIa. The gold labels were evenly distributed circumferentially around the a-granule matrix and labeling was even denser around the granules than on the OCS membranes. Identical localization on the internal face of a-granule membranes was also obtained with antibodies monospecific for GPIIb (Fig 3, A and B) or GPIIIa (Fig 3, C  and D) , confirming the presence of both peptide components in the a-granule membrane. When the primary antisera were replaced by nonimmune rabbit antisera, labeling of the different platelet organelles was absent.
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ThrombinStimulated Platelets
When platelets were stimulated by thrombin and had achieved complete degranulation, no labeling was observed within the cytoplasm, while the plasma membrane and OCS channels displayed increased labeling for GPlIb-IIIa (Fig   3E) .
G T Platelets
No labeling for either GPllb-IIIa, GPlIb, or GPIlla was observed on the platelet membranes and a-granule walls (Fig  4A) .
Gray Platelet Syndrome
GPllb-IIla was not only observed on the plasma and OCS membranes of gray platelets, but also in very small granular formations within the cytoplasm: these granules, previously described by US,'^ were consistently labeled for GPIlb-llla (Fig 4B) . Some empty vacuoles, the size of a normal a-granule (that we had interpreted earlier as "phantom a-granules" deprived of their content), also displayed gold labels on the internal side of their membrane. Other small granules (peroxisomes or lysosomes), dense bodies, and mitochondria were negative. Finally, the large vacuoles identical to those containing GMP 14OZ2 were also labeled.
Cultured M K
In immature MK, labeling for GPIIb-IIla was detected in the lumen of the Golgi saccules and associated vesicles (Fig  5, A and B) . Immature small a-granules displayed gold labeling along the inside of the wall and occasionally over the matrix. In mature large a-granules, labeling was distributed on the internal face of the membrane (Fig SC) , but many mature a-granule membranes were unlabeled. When the antibodies specific either for GPIlb or GPIIla were used separately, the same labeling was obtained, ie, the presence of both components of the complex in Golgi-associated vesicles and membranes of the a-granule precursors.
DISCUSSION
In this study, immunoreactivity for GPIIb-llla has been found to be associated in normal platelets with the external side of the plasma membrane, the intraluminal face of OCS, and the a-granule wall. This latter localization had previously been suggested by biochemical data'." showing an increase in membrane-associated receptor sites after thrombin stimulation and degranulation. More direct evidence was recently provided by Wencel-Drake et all2 by a similar immunoelectron microscopic technique. However, these immunocytochemical findings of GPIIb-IIIa in the a-granules could not be reproduced with MoAbs that heavily stained the plasma membrane and OCS of platelets, and one could speculate as to whether the polyclonal antibody that labeled the a-granule membranes was not specific but would crossreact with G M P 140. Also, arguing against the hypothesis of a putative intracellular granule pool of GPIIb-IIIa, Parise and Phillipsi3 found that treatment of platelets with neuraminidase presumably affecting only surface molecules desialated all platelet-associated GPIIb-IIIa.
Using immunogold staining technique on platelet-frozen thin sections, Ash et all4 and Nurden et a12' were unable to unequivocally define the subcellular location of intraplatelet GPIIb-IIIa. Intracellular GPIIb-IIIa was shown but was consistent with surface canalicular distribution. The specificity of our findings was confirmed by assaying platelets from a patient with GT type I: no staining was observed either on plasma membranes, OCS, or on the thrombasthenic platelet a-granules.
It is also noteworthy that GPIIIa is associated to the a-chain of the vitronectin receptor in endothelial cells2' and probably also in platelets.24 To determine whether GPIIIa was associated to GPIIb in the a-granule membrane as well as in the plasma membrane, if it was present alone, or if it was associated with the vitronectin receptor, we used specific immunolabeling against both peptide components of the GPIIb-IIIa complex: we found that GPIIIa is associated with GPIIb in the a-granule pool, similar to what is found on the platelet surface.
The study of three patients with the GPS'6*25 showed that the small abnormal a-granules previously observed in their platelets also contained GPIIb-IIIa, like normal a-granule precursors, as well as some empty vacuoles the size of normal a-granules, which we interpreted earlier as "phantom" abnormal a-granules.I6 This was in agreement with the findings of Rosa et aIz6 who found a normal amount of the a-granule membrane protein GMP-140 in gray platelets and hypothesized an abnormality of targeting of normally synthesized a-granule proteins to the developing a-granules.
The localization of GPIIb-IIIa in both the cellular membranes and the granule membranes made the study of its appearance in MK of particular interest. We recently demonstrated that fibrinogen, which is stored in M K a-granules, was appearing late in M K maturation, much later than other synthesized a-granule proteins such as von Willebrand factor and thrombospondin." Moreover, it is suggested that M K fibrinogen can be endocytosed from the external Although it was tempting to hypothesize a coordinated appearance of both fibrinogen and its receptor GPIIb-IIIa in the a-granule at late maturation stage, this was not the case: GPIIb-IIla was detected in the Golgi saccules and associated vesicles of immature MK, and simultaneously in the small a-granule precursors as well as the first forming demarcation membrane; the appearance of GPIIb, IIIa, and the complex long before fibrinogen is retained in the a-organelle is of interest and merits further elucidation. This type of both granule and membrane localization can be compared with that of LFA-1 and Mol in neutrophil^,^^.^' and it would be of interest to know by which mechanism the forming protein is transferred from the Golgi apparatus either to the plasma membrane or the granule membrane. Finally, to explain the concentration of exogenous fibrinogen within the MK a-granules a t a late stage of their maturation, it would be interesting to know if the conformation of a-granule GPIIbIIIa is in an activated form, different from its conformation in the plasma membrane.
